TCGA-91-6830-01A-11R-1949-07
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
- age_years
- 65
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.450
- INTERFERON_GAMMA_RESPONSE+0.360
- PROTEIN_SECRETION+0.350
- MYOGENESIS+0.330
- UV_RESPONSE_DN+0.330
- KRAS_SIGNALING_UP+0.320
- COAGULATION+0.310
- COMPLEMENT+0.310
- IL6_JAK_STAT3_SIGNALING+0.290
- ANGIOGENESIS+0.250
Top 10 suppressed
- MYC_TARGETS_V2-0.590
- E2F_TARGETS-0.540
- G2M_CHECKPOINT-0.500
- MYC_TARGETS_V1-0.450
- OXIDATIVE_PHOSPHORYLATION-0.400
- DNA_REPAIR-0.370
- CHOLESTEROL_HOMEOSTASIS-0.290
- WNT_BETA_CATENIN_SIGNALING-0.230
- MTORC1_SIGNALING-0.200
- GLYCOLYSIS-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-49-6744-01A-11R-1858-07 | — | cohortA1 | 0.890 |
| 2 | TCGA-CR-7392-01A-11R-2016-07 | — | — | 0.889 |
| 3 | MDT-AP-3282 | Med | Medulloblastoma | 0.874 |
| 4 | SRR2016976 | — | — | 0.870 |
| 5 | TCGA-99-7458-01A-11R-2039-07 | — | cohortA1 | 0.866 |
| 6 | ERR2598341 | fetal | fetal | 0.863 |
| 7 | TCGA-J2-8192-01A-11R-2241-07 | — | cohortA1 | 0.858 |
| 8 | d552ba81-1140-4ab6-a14c-659c07e494d0 | — | — | 0.858 |
| 9 | TCGA-22-4596-01A-01R-1201-07 | — | cohortA1 | 0.856 |
| 10 | TCGA-44-A4SS-01A-11R-A24X-07 | — | cohortA1 | 0.854 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.450 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.360 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.350 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.330 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.330 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.320 | Inavolisib | — uncovered |
| COAGULATION | 0.310 | Binimetinib | — uncovered |
| COMPLEMENT | 0.310 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.290 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.250 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.250 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.240 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.220 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.210 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.170 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.150 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.140 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.120 | Idelalisib | — uncovered |